Shares of Clovis Oncology (NASDAQ:CLVS) have earned an average rating of “Buy” from the sixteen brokerages that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $83.06.

Several research analysts have recently commented on the company. ValuEngine upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 2nd. Gabelli reiterated a “buy” rating on shares of Clovis Oncology in a research note on Monday, July 16th. BidaskClub upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 12th. Zacks Investment Research downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Finally, Cann assumed coverage on Clovis Oncology in a research note on Wednesday, August 8th. They set a “hold” rating for the company.

Shares of NASDAQ CLVS opened at $35.08 on Wednesday. The company has a quick ratio of 9.21, a current ratio of 10.03 and a debt-to-equity ratio of 1.84. Clovis Oncology has a 12 month low of $33.85 and a 12 month high of $86.26. The company has a market cap of $1.88 billion, a PE ratio of -6.85 and a beta of 1.02.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.56). Clovis Oncology had a negative return on equity of 94.28% and a negative net margin of 382.83%. The business had revenue of $23.76 million for the quarter, compared to the consensus estimate of $22.44 million. During the same quarter in the prior year, the firm posted ($1.29) earnings per share. The business’s revenue was up 62.5% compared to the same quarter last year. research analysts expect that Clovis Oncology will post -6.77 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the company. Trexquant Investment LP acquired a new position in shares of Clovis Oncology in the first quarter valued at $3,012,000. American Century Companies Inc. raised its stake in shares of Clovis Oncology by 28.3% in the first quarter. American Century Companies Inc. now owns 66,937 shares of the biopharmaceutical company’s stock valued at $3,534,000 after purchasing an additional 14,782 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Clovis Oncology by 7,640.2% in the first quarter. Victory Capital Management Inc. now owns 14,629 shares of the biopharmaceutical company’s stock valued at $772,000 after purchasing an additional 14,440 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Clovis Oncology by 18.5% in the first quarter. Prudential Financial Inc. now owns 60,109 shares of the biopharmaceutical company’s stock valued at $3,174,000 after purchasing an additional 9,369 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Clovis Oncology by 2.3% in the first quarter. Swiss National Bank now owns 80,850 shares of the biopharmaceutical company’s stock valued at $4,269,000 after purchasing an additional 1,800 shares in the last quarter.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Article: Fundamental Analysis and Individual Investors

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.